PARP1 and renal fibrosis: The main findings of this work are that inhibition of PARP1 with 5-AIQ ameliorates renal dysfunction and prevents body weight loss, decreasing renal fibrosis and tubular lesions in CisPt treated rats 2 weeks after the treatment.